{"id":515608,"date":"2021-07-21T08:04:14","date_gmt":"2021-07-21T12:04:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/"},"modified":"2021-07-21T08:04:14","modified_gmt":"2021-07-21T12:04:14","slug":"enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/","title":{"rendered":"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <strong>Nes Ziona, Israel, July  21, 2021  (GLOBE NEWSWIRE) &#8212; <\/strong>Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its CEO, Dr. Oren Hershkovitz, will participate in, and provide an interview at, the virtual Improvate Life-Saving Technologies International Conference 2021 being held on Thursday, July 22, 2021. During the interview, which will take place at approximately 5:15 AM EDT (12:15 PM Israel time), Dr. Hershkovitz will discuss the Company\u2019s Allocetra<sup>TM<\/sup> macrophage reprogramming cell therapy platform, which is being developed for life-threatening unmet medical conditions, and the Company\u2019s current development plans.\u00a0 <\/p>\n<p>The live broadcast can be accessed by registering through the conference\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UEJ0WCx7tTdyD3kFffaRK1xIU4QYy226H6_K0EW6ezStVRpD9BHGh29ExgXQ3hVifBCkWtbnXhtwoF0Dxarbk7YVLurfv9QLl4Ss-fEyLpXt-wbkQDLmlcd0JcGM5RVT5-5BnZTLYcBRFbt1jdDRjpOHQiR1ert-PuPuR-aOSrE=\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/improvate.net\/life_saving_technologies_2021\/<\/u><\/a>. <\/p>\n<p>\n        <strong>ABOUT IMPROVATE AND THE LIFE-SAVING TECHNOLOGIES INTERNATIONAL CONFERENCE 2021<\/strong>\n      <\/p>\n<p>IMPROVATE is a platform that makes technology and innovation accessible to countries around the world, with an emphasis on advancing Israeli technologies. Launched in September 2020, IMPROVATE operates out of London and Tel Aviv and serves as a platform to connect leaders, decision makers, companies, and investors with technology and innovation companies. IMPROVATE works through international conferences and business delegations and promotes deals between governments, organizations and investors with technology and innovation companies. Among IMPROVATE\u2019s Board members are former world chess champion Garry Kasparov, former Bulgarian President Rosen Plevneliev (2010-2017), and IDF Major Gen. (Ret.) Amos Gilad. The Improvate Life-Saving Technologies International Conference 2021 \u00a0will be attended by health and science ministers from several countries in Europe, and will focus on potentially life-saving technologies.<br \/>\u00a0\u00a0<br \/><strong>ABOUT ALLOCETRA<sup>TM<\/sup><\/strong><\/p>\n<p>Allocetra<sup>TM<\/sup> is being developed as a universal, off-the-shelf cell therapy designed to\u00a0reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra<sup>TM<\/sup> has the potential to provide a novel immunotherapeutic mechanism of action\u00a0for life-threatening clinical indications that are defined as \u201cunmet medical needs\u201d, as a stand-alone therapy or in combination with leading therapeutic agents. <\/p>\n<p>\n        <strong>ABOUT ENLIVEX<\/strong>\n      <\/p>\n<p>Enlivex is a clinical stage immunotherapy company developing Allocetra<sup>TM<\/sup>, a universal, off-the-shelf cell therapy designed to\u00a0reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dmSejAw_vmne6z2UE-7_jMBhVHWwOE5EHNORHGXDXzzFaBEdxgRH-UJ5kibenKGM45qU_KjM3ifRlOvqrrrs_XxoA8b-ERQPqGEVPR_WApM=\" rel=\"nofollow noopener\" target=\"_blank\"><u>http:\/\/www.enlivex.com.<\/u><\/a><\/p>\n<p>\n        <em>Safe Harbor Statement:\u00a0 This press release contains forward-looking statements, which may be identified by words such as \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cshould,\u201d \u201cwould\u201d, \u201ccould,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201csuggests,\u201d \u201chas the potential to\u201d and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<sup>TM<\/sup>\u00a0programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\u00a0 Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex\u2019s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and\/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<sup>TM<\/sup>\u00a0product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.\u00a0 In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex\u2019s filings with the Securities and Exchange Commission, including in the Company\u2019s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.\u00a0 The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.<\/em>\n      <\/p>\n<p>\n        <strong>ENLIVEX CONTACT<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/> Shachar Shlosberger, CFO\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/> Enlivex Therapeutics, Ltd.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eAQFInJiIJzjRnbxQfottiyvPUH8ioz32s2owxFWmFSXdWZE32MwAr0bBKGxrB3ah8qyeEazwoDduL-QEUzYPRO4eEgh1i1jYbuY1FApAfA=\" rel=\"nofollow noopener\" target=\"_blank\"><u>shachar@enlivexpharm.com<\/u><\/a><\/p>\n<p>\n        <strong>INVESTOR RELATIONS CONTACT<\/strong><br \/>\n        <br \/>Eric Ribner<br \/>LifeSci Advisors<br \/>eric@lifesciadvisors.com<\/p>\n<p align=\"justify\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n<hr \/>\n<p>\n        \n      <\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/562516b2-ff7a-44d8-84a9-c82af585be96\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nes Ziona, Israel, July 21, 2021 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its CEO, Dr. Oren Hershkovitz, will participate in, and provide an interview at, the virtual Improvate Life-Saving Technologies International Conference 2021 being held on Thursday, July 22, 2021. During the interview, which will take place at approximately 5:15 AM EDT (12:15 PM Israel time), Dr. Hershkovitz will discuss the Company\u2019s AllocetraTM macrophage reprogramming cell therapy platform, which is being developed for life-threatening unmet medical conditions, and the Company\u2019s current development plans.\u00a0 The live broadcast can be accessed by registering through the conference\u2019s website at https:\/\/improvate.net\/life_saving_technologies_2021\/. ABOUT IMPROVATE AND THE LIFE-SAVING TECHNOLOGIES INTERNATIONAL CONFERENCE 2021 IMPROVATE &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-515608","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Nes Ziona, Israel, July 21, 2021 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its CEO, Dr. Oren Hershkovitz, will participate in, and provide an interview at, the virtual Improvate Life-Saving Technologies International Conference 2021 being held on Thursday, July 22, 2021. During the interview, which will take place at approximately 5:15 AM EDT (12:15 PM Israel time), Dr. Hershkovitz will discuss the Company\u2019s AllocetraTM macrophage reprogramming cell therapy platform, which is being developed for life-threatening unmet medical conditions, and the Company\u2019s current development plans.\u00a0 The live broadcast can be accessed by registering through the conference\u2019s website at https:\/\/improvate.net\/life_saving_technologies_2021\/. ABOUT IMPROVATE AND THE LIFE-SAVING TECHNOLOGIES INTERNATIONAL CONFERENCE 2021 IMPROVATE &hellip; Continue reading &quot;Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-21T12:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021\",\"datePublished\":\"2021-07-21T12:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/\"},\"wordCount\":790,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/\",\"name\":\"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==\",\"datePublished\":\"2021-07-21T12:04:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/","og_locale":"en_US","og_type":"article","og_title":"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021 - Market Newsdesk","og_description":"Nes Ziona, Israel, July 21, 2021 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its CEO, Dr. Oren Hershkovitz, will participate in, and provide an interview at, the virtual Improvate Life-Saving Technologies International Conference 2021 being held on Thursday, July 22, 2021. During the interview, which will take place at approximately 5:15 AM EDT (12:15 PM Israel time), Dr. Hershkovitz will discuss the Company\u2019s AllocetraTM macrophage reprogramming cell therapy platform, which is being developed for life-threatening unmet medical conditions, and the Company\u2019s current development plans.\u00a0 The live broadcast can be accessed by registering through the conference\u2019s website at https:\/\/improvate.net\/life_saving_technologies_2021\/. ABOUT IMPROVATE AND THE LIFE-SAVING TECHNOLOGIES INTERNATIONAL CONFERENCE 2021 IMPROVATE &hellip; Continue reading \"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-21T12:04:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021","datePublished":"2021-07-21T12:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/"},"wordCount":790,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/","name":"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==","datePublished":"2021-07-21T12:04:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MzY1NSM0MzA2MjI3IzUwMDA2NTE3NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/515608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=515608"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/515608\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=515608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=515608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=515608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}